MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells
作者： Lucy Liu , Nicolas Gaboriaud , Konstantina Vougogianopoulou , Yan Tian , Jun Wu
DOI: 10.4161/CBT.26721
关键词: Janus kinase 、 STAT3 、 Janus kinase 2 、 Cancer research 、 Cancer cell 、 Tyrosine kinase 、 Kinase 、 Tyrosine-protein kinase CSK 、 Proto-oncogene tyrosine-protein kinase Src 、 Biology
摘要: … kinase inhibitory activity and anticancer activity of MLS-2384. Our data from in vitro kinase … MLS-2384 is a dual JAK/Src kinase inhibitor, and suppresses growth of various human cancer …
sci-hub.se 参考文章(46)
Gregory P. Kouraklis, Nikolaos A. Chatzizacharias, Constantinos Giaginis, Stamatios E. Theocharis, Clinical significance of Src expression and activity in human neoplasia Histology and Histopathology. ,vol. 27, pp. 677- 692 ,(2012) , 10.14670/HH-27.677
A. Tadlaoui Hbibi, C. Lagorce, P. Wind, J.P. Spano, G. Des Guetz, G. Milano, R. Benamouzig, O. Rixe, J.-F. Morere, J.-L. Breau, A. Martin, R. Fagard, Identification of a functional EGF-R/p60c-src/STAT3 pathway in colorectal carcinoma: analysis of its long-term prognostic value. Cancer Biomarkers. ,vol. 4, pp. 83- 91 ,(2008) , 10.3233/CBM-2008-4204
Ralph Hoessel, Sophie Leclerc, Jane A. Endicott, Martin E. M. Nobel, Alison Lawrie, Paul Tunnah, Maryse Leost, Eve Damiens, Dominique Marie, Doris Marko, Ellen Niederberger, Weici Tang, Gerhard Eisenbrand, Laurent Meijer, Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases Nature Cell Biology. ,vol. 1, pp. 60- 67 ,(1999) , 10.1038/9035
Hua Yu, Richard Jove, The STATs of cancer — new molecular targets come of age Nature Reviews Cancer. ,vol. 4, pp. 97- 105 ,(2004) , 10.1038/NRC1275
Richard Jove, Michelle A. Blaskovich, Jiazhi Sun, Saïd M. Sebti, Alan Cantor, James Turkson, Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Research. ,vol. 63, pp. 1270- 1279 ,(2003)
M. C. Frame, Newest findings on the oldest oncogene; how activated src does it. Journal of Cell Science. ,vol. 117, pp. 989- 998 ,(2004) , 10.1242/JCS.01111
E J Wojcik, S Sharifpoor, N A Miller, T G Wright, R Watering, E A Tremblay, K Swan, C R Mueller, B E Elliott, A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells Oncogene. ,vol. 25, pp. 2773- 2784 ,(2006) , 10.1038/SJ.ONC.1209306
Rami Komrokji, Srdan Verstovsek, Assessing efficacy in myelofibrosis treatment: a focus on JAK inhibition. Expert Review of Hematology. ,vol. 5, pp. 631- 641 ,(2012) , 10.1586/EHM.12.50
Stephen Y. Lai, Faye M. Johnson, Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resistance Updates. ,vol. 13, pp. 67- 78 ,(2010) , 10.1016/J.DRUP.2010.04.001
Zhijian Xiao, Yushu Hao, Bingcheng Liu, Lingsheng Qian, Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leukemia & Lymphoma. ,vol. 43, pp. 1763- 1768 ,(2002) , 10.1080/1042819021000006295